Table 3.
Diabetes treatment satisfaction questionnaire scores at baseline and 12 weeks in patients who completed the study
| Vildagliptin | P * | Liraglutide | P * | P ** | |||
|---|---|---|---|---|---|---|---|
| Before | After | Before | After | ||||
| Q1 | 4.1 ± 1.4 | 3.9 ± 1.4 | 0.424 | 4.0 ± 0.7 | 4.0 ± 1.3 | 0.873 | 0.628 |
| Q2 | 3.1 ± 1.7 | 2.8 ± 2.0 | 0.503 | 3.6 ± 1.7 | 3.3 ± 0.3 | 0.312 | 0.958 |
| Q3 | 1.6 ± 1.6 | 1.2 ± 1.6 | 0.437 | 1.4 ± 1.6 | 1.5 ± 1.6 | 0.747 | 0.400 |
| Q4 | 4.3 ± 1.6 | 4.8 ± 1.0 | 0.117 | 4.3 ± 1.4 | 4.3 ± 1.3 | 0.759 | 0.300 |
| Q5 | 4.2 ± 1.6 | 4.5 ± 1.2 | 0.348 | 4.2 ± 1.0 | 4.0 ± 1.4 | 0.527 | 0.264 |
| Q6 | 4.0 ± 1.4 | 4.3 ± 0.9 | 0.296 | 4.3 ± 0.9 | 3.9 ± 1.4 | 0.236 | 0.113 |
| Q7 | 3.9 ± 1.5 | 4.2 ± 1.2 | 0.492 | 4.2 ± 1.1 | 4.1 ± 1.4 | 0.780 | 0.473 |
| Q8 | 4.0 ± 1.5 | 4.2 ± 1.3 | 0.700 | 4.2 ± 1.0 | 4.0 ± 1.4 | 0.548 | 0.495 |
| SUM | 25.5 ± 6.3 | 25.8 ± 5.6 | 0.794 | 25.1 ± 4.7 | 24.4 ± 7.3 | 0.579 | 0.595 |
Data are expressed as mean ± standard deviation.
*
P-value for the intragroup comparison (baseline vs 12 weeks);
**
P-value for the intergroup comparison (difference in changes from baseline between groups).